Trial Profile

Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRX 2 (Primary) ; Nivolumab (Primary) ; Cyclophosphamide
Indications Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Mar 2025 According to a Ernexa Therapeutics media release, the Eterna Therapeutics has changed its name to Ernexa Therapeutics.
26 Aug 2019 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
26 Aug 2019 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com